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Description of  pathologic causes of  cervical lymphadenopathy at Kamuzu 
Central Hospital.
The evaluation of  cervical lymphadenopathy is a common diagnostic 
challenge facing clinicians. Previously at Kamuzu Central Hospital (KCH) 
tuberculosis (TB) was reported to be the most common cause of  cervical 
lymphadenopathy However, no recent study has assessed this common 
diagnostic challenge in Malawi, particularly since the beginning of  the 
HIV epidemic and the subsequent scale-up of  antiretroviral therapy.
We conducted a cross-sectional study of  all cervical lymph node specimens 
from the KCH pathology laboratory between 1 July 2011 and 28 February 
2013 and describe patient age, gender, and pathologic diagnoses.
Our search of  the KCH pathology database yielded 179 cases. Of  these, 
143 (77%) were histologic specimens (open biopsy or core needle samples) 
while 34 (23%) were cytology specimens. The age range was from 0 
to 76 years with a mean of  30 (SD: 19). In adults, the most common 
diagnosis was malignancy (n=41, 35%), while in children 15 cases each 
of  malignancy and benign masses were diagnosed. Only 6 cases (5%) of  
TB were diagnosed in adults, and 4 cases (6%) of  TB were diagnosed in 
children.
Our study shows more malignancy and much less TB than a prior study 
of  cervical lymphadenopathy at KCH. With the successful initiaion of  
the KCH Pathology Laboratory in 2011, we recommend biopsy or FNA 
early in the workup of  cervical lymphadenopathy to prevent long delays in 
diagnosis and treatment of  curable cancers.
Cervical lymphadenopathy is the commonest form of  
peripheral lymphadenopathy1. It has many causes, including 
benign, infectious and malignant conditions. The evaluation 
of  cervical lymphadenopathy is a common diagnostic 
challenge facing clinicians. While a careful history and 
thorough physical exam can help identify the cause of  
diagnostic test. Open biopsy is time consuming and costly, 
requiring theatre time and anesthesia. Fine needle aspiration 
(FNA) is less invasive, cheaper, and quicker. However, 
cytology from FNA specimens may have diagnostic 
limitations for many conditions compared with histologic 
evaluation of  biopsy specimens. FNA analysis additionally 
requires a well-trained pathologist and is best done onsite, 
both rare commodities in many parts of  sub-Saharan 
Africa2. Core needle biopsy is an intermediate technique 
in terms of  cost, time, and information obtained, but can 
be dangerous in the neck, especially when performed by 
clinicians who are inadequately trained3. A clinician may also 
choose to empirically treat for tuberculosis (TB) or bacterial 
infection based on history and physical examination, and 
reserve biopsy or FNA for patients who do not respond to 
and treatment of  a malignancy. The optimal strategy for 
evaluating cervical lymphadenopathy in resource-limited 
settings like Malawi is largely unknown given the relative 
advantages and disadvantages of  these varying approaches, 
particularly in light of  recent expansion of  diagnostic 
pathology services to Lilongwe.
A large body of  literature suggests that TB is the most 
common cause of  cervical lymphadenopathy in sub-
Saharan Africa, accounting for 17-66% of  cases1, 4, 6-23. In 
Malawi, at Kamuzu Central Hospital (KCH) during the 
years 1985-1988, TB was reported to be most common 
cause lymphadenopathy4. However, no recent study has 
assessed causes of  cervical lymphadenopathy in Malawi in 
the modern era, particularly since the beginning of  the HIV 
epidemic and rapid scale-up of  antiretroviral therapy (ART) 
nationwide among HIV-infected individuals. Currently, more 
than 60% of  those needing ART are now receiving it5. In this 
study, we describe the pathological diagnoses for patients 
with cervicallymphadenopathy presenting to KCH who 
underwent a diagnostic biopsy. We also suggest strategies to 
improve diagnosis and management of  patients with cervical 
lymphadenopathy.
The KCH Pathology Laboratory became operational in 
July 2011 with Professor George Liomba now reviewing 
specimens and providing laboratory direction. Two histology 
and cytology technicians underwent training in South Africa 
and have returned to staff  the laboratory. The lab currently 
accepts specimens from KCH outpatient clinics, inpatient 
wards and operating rooms. During the period reported in 
this paper, diagnoses were based on morphology without the 
or molecular diagnostic tools. IHC methods, however, are 
now being introduced. Operating procedures, as well as 
quality assessment and control systems have been clearly 
established, and include regular review by UNC pathologists 
to insure diagnostic accuracy during weekly real-time 
telepathology conferences using the virtual microscopy 
system.
At the time of  specimen collection and submission to the 
laboratory, requesting clinicians complete a standardised 
pathology requisition form, including patient demographics 
(age, gender, HIV status, antiretroviral therapy status), brief  
clinical information, and specimen details (including site 
of  biopsy, type of  specimen, and date of  collection). The 
laboratory then assigns each specimen a unique laboratory 
number, and enters details from the requisition form as well 
as specimen information and the pathologist’s conclusions 
into a secure KCH pathology database. Longitudinal data 
regarding clinical course and treatment is not available.
Review of  the database was approved by the Malawi 
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National Heath Services Committee(protocol ##1124) and 
the UNC Internal Review Board (UNC IRB # #13-0047). 
We conducted a retrospective cross-sectional study of  all 
cervical lymph node specimens from the KCH pathology 
laboratory between 1 July 2011 and 28 February 2013. 
Salivary glands (submandibular and sublingual) biopsies were 
also included, as they often contain nodal tissue. Mandible, 
facial and thyroid masses were excluded. Diagnoses were 
categorized as non-diagnostic, malignant, tuberculosis, non-
tuberculous infection, reactive adenopathy, benign mass 
(i.e., pleomorphic adenoma, lipoma, pyogenic granuloma), 
normal tissue, or other process. According to usual local 
practice, tuberculosis was diagnosed typically based on cha 
the demonstration of  mycobacteria by smear or culture 
in most cases. Data were entered into Microsoft excel 
spreadsheets and Stata 12 (StatCorp, College Station, Texas, 
USA) was used for all analyses. Descriptive statistics were 
used to measure numbers of  specimens assessed, specimen 
means between patients with non-diagnostic specimens were 
analyzed using chi-square. Pediatric cases were analyzed 
from the cervical lymph nodes. search of  the KCH pathology 
database yielded a total of  179 cases of  cervical adenopathy. 
Of  these, 143 (77%) were histologic specimens (open biopsy 
or core needle samples) while 34 (23%) were cytology 
specimens. The age range was from 0 to 76 years with a mean 
of  30 (SD: 19). Adults (16 years of  age or older) accounted 
for 121 (68%) of  the study population with a mean age of  40 
(SD: 15). Women accounted for 65 (54%) of  adult cases. The 
mean age among pediatric cases was 8 years (SD: 5, n=58). 
Of  the 58 paediatric cases, 35 (60%) were female (Table 1).
Table 1: Characteristics of Neck Node Biopsy Patients (n=179) at KCH 
from July 2011 to February 2013
CHARACTERISTIC MEAN or N* SD or %
Pediatric patients (< 16
years)
58 33%






Age (years) 40.4 14.4%
Male 53 44.9%
Female 65 55.1%
* Gender is missing for one pediatric case, and age is missing in three 
cases, therefore percentages are based on totals excluding missing 
patients. KCH- Kamuzu Central Hospital
The most common diagnosis in adults was malignancy 
(n=41, 35%), followed by benign mass (n=25, 21%), non-
TB infection (n=17, 14%), non-diagnostic cases (n=13, 
11%), reactive adenopathy and normal tissue (n=7, 6%) 
each. TB accounted for 6 (5%) of  cases (Table 2). Of  the 
41 adult malignancies cases, 11 (27%) were non-Hodgkin’s 
lymphoma (NHL), 10 (24%) were squamous cell carcinoma 
(SCC). Four (10%) were nasopharyngeal carcinoma (NPC), 
4 sarcoma (excluding KS), and 1 (2%) Hodgkin’s lymphoma. 
A third of  the biopsies (n = 58) were from children. (Table 
1). Among children, malignancy and benign masses were the 
most common, with 15 cases (26%) each (Table 2). 
Table 2 Frequency of Histopathological Diagnosis in Lymph Node 
Biopsies at KCH from July 2011 to February 2013
Non-diagnostic specimens accounted for 7 cases (12% 
Non-tuberculous infection, reactive nodes, and normal 
tissue each accounted for 5 cases (9%). TB was diagnosed 
in 4 cases (7%). Of  the 15 pediatric malignancies, Hodgkin’s 
lymphoma was the commonest with 6 cases (40%), followed 
case of  non-Hodgkin’s lymphoma (Table 3).
Of  the 21 non-diagnostic cases, 14 (67%) were from FNA 
specimens and 7 (33%) were from histology specimens. In 
total, one-third of  all FNA specimens were inadequate for 
diagnosis, while only 9 (6%) histologic specimens were non-
diagnostic. FNA specimens had a 9.3 times greater odds of  












Reactive adenopathy 5 8.6%
Normal Tissue 5 8.6%
TB 4 6.9%










Reactive adenopathy 7 5.9%
Normal tissue 7 5.9%
TB 6 5.1%
Other process 2 1.7%
Total 176
* Age is missing in three cases, therefore percentages are based on 
totals excluding missing patients.
Cervical lymphadenopathy  18
Table 3 Malignancies Diagnosed in Lymph Node Biopsies in Adult and 
Pediatric Patients at KCH from July2011 to February 2013
The pathologic diagnosis of  biopsied cervical lymphnodes 
at KCH has changed markedly over the past 20 years, and 
Saharan countries. In our population, we found more 
malignancy and little TB . In our population, less than 10% 
of  cervical lymphadenopathy were diagnosed with TB. TB 
prevalence and mortality have declined in Malawi over the 
past two decades, and prevalence in Malawi (164/100,000) 
(490/100,000) and Zambia (352/100,000)24. While reported 
TB cases have modestly declined over the past two decades, 
node biopsies at KCH than a study at the same institution 25 
years ago4. In Malawi, over 5,000 cases of  extrapulmonary 
TB were diagnosed in 2011 alone24. While the apparent 
decline in TB as a cause of  cervical lymphadenopathy at 
that patients who respond to empiric TB treatment may not 
undergo FNA or biopsy for cervical lymphadenopathy. In 
our study, malignancy is also more common than described 
in the previous KCH study4. We found that one in three 
cervical lymph nodes that were biopsied were malignant. The 
high proportion of  patients with cancer in our sample likely 
increasing cancer incidence overall in Malawi25. Among all 
cancer, lymphoma was the most common in both adult and 
Burkitt lymphoma, even though this disease is common in 
the region. Because Burkitt lymphoma commonly presents 
as facial or abdominal masses, which were excluded from our 
study, these patients would have been underrepresented in our 
cervicallymphadenopathy series. Squamous cell carcinoma 
(SCC) of  the head and neck was found in 10% of  the adult 
population referred for biopsy. This represents cervical 
nodal metastasis of  a likely upper aerodigestive tract primary. 
Cervical nodal SCC should prompt a search for the primary 
site in the oral cavity, oropharynx, larynx hypopharyx or lung. 
Cliniciansshould be aware that airway obstruction is common 
in these patients. The high frequency of  cancer diagnoses in 
our study suggests a need for rapid evaluation and pathologic 
diagnosis for unexplained cervical lymphadenopathy at KCH, 
such that potentially curative treatment can be provided to 
patients before they progress to more advanced stages of  
cancer which may be less amenable to cure. More than one 
in ten samples included in our study was non-diagnostic. 
Non-diagnostic samples translate to longer waiting times 
diagnosis and initiating treatment. FNA specimens had 
greater odds of  being inadequate for diagnosis, which is 
consistent with previous studies6. Previous research suggests 
that experienced clinicians who perform FNA frequently 
have greater diagnostic yield from FNA specimens26. We can 
improve the work-up and management of  neck nodes in our 
setting by biopsying patients early in the work up of  cervical 
lymphadenopathy, improving training in biopsy techniques, 
improving clinical data collection on pathology forms, 
and expanding provision of  pathology services to include 
samples from district hospitals. Since July 2011, pathology 
results have often been available within 72 hours; however, 
treating TB empirically remains the norm in referring clinics. 
This practice could will lead tocause a delay in diagnosis of  
cancer, and anedoctally we have seen many patients at KCH 
with clearly malignant masses which have been progressing 
on inappropriate TB treatment for many months before 
being referred. We hope that as pathology services become 
more available, clinicians will move away from empirical 
treatment of  TB for cervical lymphadenopathy. Clinicians 
diagnosis wherever possible to avoid delays in appropriate 
treatment. KCH is already working towards improving yield 
from FNA, and has conducted training for doctors and 
clinicians, as well as implementing an FNA clinic staffed 
by Prof. Liomba, which will help reduce the number of  
non-diagnostic cases. Preparation of  cell blocks from FNA 
specimens which can undergo IHC staining is also being 
implemented and will increase the diagnostic yield. Clinicians 
are encouraged to work closely with the pathology laboratory 
to improve specimen preparation and to avoid common 
mistakes that impede timely diagnosis. Delineating clinical 
features of  benign versus malignant cervical lymph nodes in 
our population could help prevent unnecessary biopsies of  
harmless lesions, and more importantly, prevent long delays 
in diagnosis and treatment of  curable cancers. Clinicians are 
greatly encouraged to fully complete request forms including 
clinical history and HIV status, to provide robust data for 
Diagnosis N %
Adults (>15 yrs)








Carcinoma NOS‡ 3 7
Kaposi sarcoma 2 5
Small round blue cell 
tumor NOS
2 5








Hodgkin lymphoma 6 40





Non-Hodgkin lymphoma 1 7
Total 15 100
*Excluding Kaposi sarcoma
‡ Not otherwise specified
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algorithms. Our study is limited by incomplete clinical 
information on pathology requisition forms submitted to the 
laboratory. HIV status was infrequently recorded, such that 
less than one in seven cases in our study known HIV status. 
Furthermore, clinical information was often sparse, which 
may hinder the pathologist’s diagnosis of  the individual 
specimen. These limitations are common in retrospective 
studies like ours, particularly in sub-Saharan Africa where 
clinical data systems are often weak. Additionally, our 
data are drawn froma national referral hospital. Patients 
sent to KCH months later. Our data probably do not fully 
represent patients with aggressive malignancy who died 
before presentation to KCH, or patients whose adenopathy 
resolved with TB treatment or antibiotics. 
In conclusion, our study shows more malignancy and less TB 
than a previous KCH study of  cervical lymphadenopathy. 
Continued research efforts should include a prospective 
study of  cervical lymphadenopathy, enrolling patients 
directly from clinic to minimize biases discussed above. As 
turn-around time for biopsy specimens at KCH continues 
to improve, we recommend performing biopsy or FNA 
early in the workup of  cervical lymphadenopathy to prevent 
long delays in diagnosis and treatment of  various medical 
conditions, including potentially curable cancers.
Claire Kendig and Satish Gobal are supported by the 
FogartyInternational Center (1R25TW009340-01). Satish 
Gopal is also supported by an International ResearchScientist 
Development Award from the NIH Fogarty International 
Center (1K01TW009488-01). This work was alsosupported 
by the University of  North Carolina Center for AIDS 
Research, an NIH-funded program (P30 AI50410).
1. Olu-eddo AN, Omoti CE. Diagnostic evaluation of primary cervical 
adenopathies in a developing country. Pan Afr Med J. 2011;10:52.
2. Lee J, Fernandes R. Neck masses: Evaluation and diagnostic 
approach. Oral Maxillofac Surg Clin North Am. 2008 Aug;20(3):321-
37
3. Gong JZ, Snyder MJ, Lagoo AS, Vollmer RT, Dash RR, Madden JF, 
of non-hodgkin lymphoma. Diagn Cytopathol. 2004 Jul;31(1):23-30.
4. Nkhoma W, Wirima J J. Review of Lymph Node Biopsies: Medical 
Ward, Kamuzu Central Hospital, 1985-1988. Malawi Med J. 1991 
Jan;7(1):25-7.
5. UNAIDS (2012) Global AIDS Response Progress Report: Malawi 
Country Report for 2010 and 2011.Available: http://www.unaids.org/
en/dataanalysis/knowyourresponse/countryprogressreports/2012countr
Med J. 2003 Nov;80(11):559-63.
7.  Getachew A, Demissie M, Gemechu T. Pattern of histopathologic 
diagnosis of lymph node biopsies in a teaching hospital in Addis Ababa, 
1981-1990 G.C. Ethiop Med J. 1999 Apr;37(2):121-7.
8. Kheiry J, Ahmed ME. Cervical lymphadenopathy in Khartoum. J 
Trop Med Hyg. 1992 Dec;95(6):416-9.
9. Moore SW, Schneider JW, Schaaf HS. Diagnostic aspects of cervical 
lymphadenopathy in children in the developing world: A study of 1,877 
surgical specimens. Pediatr Surg Int. 2003 Jun;19(4):240-4.
10. Muthuphei MN. Cervical lymphadenopathy at Ga-rankuwa 
hospital (South Africa): A histological review. Cent Afr J Med. 1998 
Dec;44(12):311-2.
11. Bem C, Patil PS, Bharucha H, Namaambo K, Luo N. Importance 
tuberculous lymphadenitis in patients undergoing lymph node biopsy in 
Zambia. Br J Surg. 1996 Jan;83(1):75-8.
12. Patil PS, Bem C. Wide needle aspiration cytology in the diagnosis 
of lymphadenopathy in Zambia. J Clin Pathol. 1993 Sep;46(9):806-9.
13. Sibanda EN, Stanczuk G. Lymph node pathology in Zimbabwe: A 
review of 2194 specimens. Q J Med. 1993 Dec;86(12):811-7.
14. Adelusola KA, Oyelami AO, Odesanmi WO, Adeodu OO. 
Lymphadenopathy in Nigerian children. West Afr J Med. 1996 Apr-
Jun;15(2):97-100.
15. Adeniji KA, Anjorin AS. Peripheral lymphadenopathy in Nigeria. 
Afr J Med Med Sci. 2000 Sep-Dec;29(3-4):233-7.
16. Anunobi CC, Banjo AA, Abdulkareem FB, Daramola AO, Abudu 
node diseases, in Lagos (1991-2004). Niger Postgrad Med J. 2008 
Dec;15(4):243-6.
17. Obafunwa JO, Olomu IN, Onyia NJ. Primary peripheral 
lymphadenopathy in Jos, Nigeria. West Afr J Med. 1992 Jan-
Mar;11(1):25-8.
18. Ochicha O, Edino ST, Mohammed AZ, Umar AB, Atanda AT. 
Pathology of peripheral lymph node biopsies in Kane, northern Nigeria. 
Ann Afr Med. 2007 Sep;6(3):104-8.
19. Ojo BA, Buhari MO, Malami SA, Abdulrahaman MB. Surgical 
lymph node biopsies in university of Iorin teaching hospital, Ilorin, 
Nigeria. Niger Postgrad Med J. 2005 Dec;12(4):299-304.
20. Osifo OD, Ugiagbe EE. Neck masses in children: Etiopathology in a 
tertiary center. Niger J Clin Pract. 2011 Apr-Jun;14(2):232-6.
21. Shonubi AM, Akiode O, Salami BA, Musa AA, Ntele LM. A 
accessible lesions in children. West Afr J Med. 2004 Jul-Sep;23(3):221-3.
22. Thomas JO, Ladipo JK, Yawe T. Histopathology of lymphadenopathy 
in a tropical country. East Afr Med J. 1995 Nov;72(11):703-5.
23. Thomas JO, Adeyi D, Amanguno H. Fine-needle aspiration in the 
management of peripheral lympha enopathy in a developing country. 
Diagn Cytopathol. 1999 Sep;21(3):159-62.
Accessed 8 May 2013.
25.Msyamboza KP, Dzamalala C, Mdokwe C, Kamiza S, Lemerani M, 
Dzowela T, et al. Burden of cancer in Malawi; common types, incidence 
and trends: National population-based cancer registry. BMC Res Notes. 
2012 Mar 16;5:149,0500-5-149.
26. Schwarz R, Chan NH, MacFarlane JK. Fine needle aspiration 
cytology in the evaluation of head and neck masses. Am J Surg. 1990 
May;159(5):482-5.
